08 Jun. 2026
Foresee's Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2a Platform Trial
Back to List
TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in Parkinson's disease in the SLEIPNIR Phase 2a platform trial, in collaboration with Haukeland University Hospital, Bergen, Norway.
SLEIPNIR is a multi-arm Phase 2a clinical trial platform designed to evaluate investigational disease-modifying therapies in Parkinson's disease, with focus on brain penetration, biological target engagement, and mechanistic biomarker effects. The trial has been funded by Cure Parkinson's.
Professor Charalampos Tzoulis, MD, Ph.D, Chief Investigator of the SLEIPNIR Platform and Director of the Neuro-SysMed Center of Excellence for Clinical Neurological Research and the Innovation Center for Neuroresilience (ICoN) at Haukeland University Hospital and the University of Bergen, said: "Foresee's oral ALDH2 activator, mirivadelgat, was selected through a highly competitive and scientifically rigorous process as one of several therapies to be included in SLEIPNIR. This platform is specifically designed to assess central nervous system penetration and biological target engagement in patients with Parkinson's disease. This information will be indispensable in allowing us to prioritize treatments for further development. We are very pleased to collaborate with Foresee and look forward to evaluating the therapeutic potential of ALDH2 activation in PD"
Dr. Simon Kverneng, MD, PhD, a neurology resident and experienced clinical researcher in Prof. Tzoulis' group, is the Principal Investigator of SLEIPNIR.
Dr. Ben Chien, Chief Executive Officer of Foresee, said: "This is a significant opportunity to provide further validation of mirivadelgat/ALDH2 activation as a potential treatment approach for Parkinson's, and potentially other CNS diseases. We are grateful to the SLEIPNIR team, potential participants in the study and Cure Parkinson's for their support".
Dr. Wenjin Yang, CSO at Foresee stated: "The role of ALDH2 in the pathophysiology of PD and other neurological diseases is quite compelling when looking at the current body of data. We are confident the results from this study will provide a strong foundation for further development in PD and other CNS diseases as this study will provide data related to CNS penetration and target/biomarker engagement of mirivadelgat".